

July 30, 2014

Sumitomo Dainippon Pharma Co., Ltd.

Sumitomo Dainippon Pharma Announces Revisions to Its Financial Forecasts for the Half-Year Ending September 30, 2014

Osaka, Japan, July 30, 2014 - Sumitomo Dainippon Pharma Co., Ltd. (Head Office: Osaka, Japan; President: Masayo Tada; Securities Codes: 4506, First Section of TSE) announced today that it has revised its financial forecasts for the Half-year ending September 30, 2014 as summarized below, in light of recent performance trends and other factors.

1. Revisions to the Forecasts of Consolidated Financial Results for the Half-year ending September 30, 2014 (April 1, 2014 to September 30, 2014)

(Amounts in Japanese yen million, unless otherwise specified)

	Net sales	Operating income	Ordinary income	Net income	Earnings per share
Previous Forecasts (A)	178,000	12,000	11,500	6,300	¥15.86
Revised Forecasts (B)	178,000	12,000	11,500	11,000	¥27.69
Variance in amount (B) – (A)	—	—	—	4,700	
Variance in percent (%)	—	—	—	74.6	
[Reference] Same period a year ago (Half-year ending September 30, 2013)	181,396	17,435	17,408	8,697	¥21.89

2. Reasons for the revisions

Accrual of an extraordinary income in connection with disposal of idle assets which was anticipated for the second half of the fiscal year is now expected to take place during the July – September 2014 period. The forecasted net income for the first half of fiscal 2014 is now revised to 11,000 million yen from 6,300 million yen. There is no change in the forecasts for the full year.

Cautionary statement:

Forecasts shown above are based on management's assumptions and beliefs in light of the information currently available, and involve risks and uncertainties. Actual financial results may differ materially depending on a number of factors, including economic conditions.

Contact:

Corporate Communications

Sumitomo Dainippon Pharma

TEL: +81-6-6203-1407 (Osaka)

+81-3-5159-3300 (Tokyo)